ESR1 and breast carcinoma: Given that molecules targeting ERα have already been approved for ERα-positive breast cancer and various other clinical indications, if our hypothesis is validated in prospective clinical studies, stratification of PCa by ERα status to repurpose anti-estrogens could lead to additional therapeutic options in the PCa clinical landscape.